Cantor Fitzgerald Initiates Coverage On Spero Therapeutics with Overweight Rating, Announces Price Target of $6
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsInitiationPrice Target
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Spero Therapeutics (NASDAQ:SPRO) with a Overweight rating and announces Price Target of $6.
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Spero Therapeutics (NASDAQ:SPRO) with a Overweight rating and announces Price Target of $6.